Clinician-patient insights and alignment on urothelial carcinoma care.

person Tariqa Ackbarali PlatformQ Health Education, Needham, MA info_outline Tariqa Ackbarali, Stephanie Chisolm, Scott T. Tagawa, Neal D. Shore

Authors person Tariqa Ackbarali PlatformQ Health Education, Needham, MA info_outline Tariqa Ackbarali, Stephanie Chisolm, Scott T. Tagawa, Neal D. Shore Organizations PlatformQ Health Education, Needham, MA, BCAN, Bethesda, MD, Weill Cornell Medical College of Cornell University, New York, NY, Carolina Urologic Research Center, Myrtle Beach, SC Abstract Disclosures Research Funding Pharmaceutical/Biotech Company Gilead Sciences, Inc. Background: The expansion of the treatment landscape for urothelial carcinoma (UC) including immune checkpoint inhibitors and antibody-drug conjugates (ADCs) hold the promise of improving long-term survival in patients with more advanced disease. A tethered (patient-clinician) educational initiative was designed for patients/caregivers to stay up-to-date with new therapies and for clinicians to facilitate integration of new therapies into clinical practice. Methods: Two, 1-hour online, interactive, video-based programs were designed for patients and clinicians. The patient/caregiver program was hosted on CancerCoachLive in January, 2022 and the clinician program on UroCareLive and OMedLive in December, 2022. The initiative was conducted in collaboration with LUGPA, Large Urology Group Practice Association and BCAN, Bladder Cancer Advocacy Network. Behavioral assessment of preferences and attitudes toward managing patients were examined throughout the CME series and patient/caregiver program. A planned analysis of the data from these questions determined patient and clinical impact. Outcomes from the patient program were analyzed and presented during the CME series followed by expert-identified strategies to improve clinical practice. Results: A total of 1,071 participants have engaged across both educational programs. The majority of the patient participants were in remission or had recurrent UC. Patients provided insight on what mattered most at the point of decision-making (48%), the symptoms that led to a diagnosis – hematuria (85%), and their greatest quality-of-life challenge – urinary functioning concerns (52%). Of those who have been treated previously, 83% were treated with an immunotherapy and 9% with an antibody drug-conjugate. Pre- to post-activity comparisons demonstrate a greater likelihood of participation in clinical trials. When asked about the challenges patients with UC face, the top 3 challenges identified by patients were not aligned with those identified by clinicians. Clinicians additionally identified themselves as lacking confidence (58%) in their understanding of patient’s concerns or challenges. Following the activity, clinicians were very motivated to address these concerns (88%). Clinicians identified enfortumab vedotin (44%) as the ADC with the greatest potential to improve patient outcomes and a lack of knowledge on evidence-based strategies as the primary barrier to implementing changes in practice (34%). Qualitative data from both the patient and clinician activities were captured representing write-in examples of behavioral impact which will be shared. Conclusions: The initiative contributed to the provision of valuable patient insights, patient-clinician misalignment, and clinician confidence addressing patient concerns. Increasing this awareness fostered practical strategies and discussion to improve patient-centered care.